TECX
Company Description
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (74.15M) | (57.98M) | (42.82M) | (32.18M) | (8.93M) | (119.71M) | (72.97M) | (46.36M) | (18.65M) | (4.66M) |
| EPS | -4.05 | -3.93 | -11.59 | -29.05 | -33.36 | -39.68 | -31.92 | -23.41 | -9.35 | -2.34 |
| Free Cash Flow | (60.29M) | (59.24M) | (40.96M) | (97.47M) | (14.58M) | (99.98M) | (69.25M) | (39.48M) | (16.77M) | (3.31M) |
| FCF / Share | -3.29 | -4.01 | -11.09 | -26.74 | -4.08 | -33.14 | -30.29 | -19.93 | -8.40 | -1.66 |
| Operating CF | (60.08M) | (59.08M) | (40.68M) | (97.21M) | (12.45M) | (98.80M) | (67.67M) | (37.65M) | (16.38M) | (3.31M) |
| Total Assets | 261.04M | 152.91M | 39.40M | 47.21M | 32.88M | 271.23M | 200.51M | 133.48M | 7.02M | 5.40M |
| Total Debt | 1.28M | 3.30M | 4.34M | 5.79M | 1.05M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 253.80M | 141.24M | 28.77M | 35.97M | 28.06M | 259.68M | 187.04M | 126.30M | 5.96M | 5.36M |
| Book Value | 251.33M | 140.78M | (84.64M) | (45.65M) | (14.96M) | 254.34M | 186.01M | 122.18M | 3.37M | 4.42M |
| Return on Equity | -0.30 | -0.41 | N/A | N/A | N/A | -0.47 | -0.39 | -0.38 | -5.54 | -1.05 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (25.24M) | (19.23M) | (19.04M) | (19.98M) | (15.91M) | (12.37M) | (17.72M) | (12.67M) | (15.22M) | (7.87M) | (10.05M) | (10.46M) |
| EPS | -1.34 | -1.03 | -1.02 | -1.07 | -0.93 | -0.84 | -1.20 | -4.34 | -1.82 | -2.36 | -0.68 | 18.35 |
| Free Cash Flow | (18.43M) | (14.49M) | (18.00M) | (14.75M) | (13.11M) | (16.82M) | (19.76M) | (13.38M) | (9.28M) | (11.71M) | (8.49M) | (473,000) |
| FCF / Share | -0.98 | -0.79 | -0.96 | -0.79 | -0.76 | -1.14 | -1.34 | -0.91 | -2.49 | -3.15 | -2.29 | -0.13 |
| Operating CF | (18.41M) | (14.46M) | (17.82M) | (14.72M) | (13.08M) | (16.82M) | (19.60M) | (13.38M) | (9.27M) | (11.66M) | (8.48M) | (259,000) |
| Total Assets | 246.58M | 261.04M | 277.00M | 295.31M | 314.83M | 152.91M | 168.72M | 193.91M | 92.35M | 39.40M | 15.78M | 133.84M |
| Total Debt | 4.63M | 1.28M | 1.24M | 1.94M | 2.63M | 3.30M | 2.98M | 3.44M | 4.12M | 4.34M | 4.77M | 2.38M |
| Cash & Equiv | 236.89M | 253.80M | 268.44M | 287.38M | 306.25M | 141.24M | 159.09M | 185.12M | 90.76M | 28.77M | 6.33M | 124.97M |
| Book Value | 230.42M | 251.33M | 267.53M | 283.77M | 301.04M | 140.78M | 150.36M | 166.37M | 88.84M | (84.64M) | (79.78M) | 122.04M |
| Return on Equity | -0.11 | -0.08 | -0.07 | -0.07 | -0.05 | -0.09 | -0.12 | -0.08 | -0.17 | N/A | N/A | -0.09 |
